Journal of Surgery Concepts & Practice >

2022 , Vol. 27 >Issue 01: 6 - 10

DOI: https://doi.org/10.16139/j.1007-9610.2022.01.002

Editorial

Resectable pancreatic cancer: diagnosis criterion, treatment and controversy

Expand

Received date: 2021-11-30

  Online published: 2022-03-09

Fold

Cite this article

HE Min, LIU Yingbin . Resectable pancreatic cancer: diagnosis criterion, treatment and controversy[J]. Journal of Surgery Concepts & Practice, 2022 , 27(01) : 6 -10 . DOI: 10.16139/j.1007-9610.2022.01.002

References

[1] Siegel R, Ma J, Zou Z, et al. Cancer statistics,2014[J]. CA Cancer J Clin, 2014, 64(1):9-29.
[2] Margaret A, Tempero MD, Mokenge P, et al. Pancreatic adenocarcinoma,version 2.2021[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457.
[3] Mehta VK, Fisher G, Ford JA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas[J]. J Gastmintest Surg, 2001, 5(1):27-35.
[4] Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic adenocarcinoma,version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(3):202-210.
[5] Loyer EM, David CL, Dubrow RA, et al. Vascular involvement in pancreatic adenocarcinoma:reassessment by thin-section CT[J]. Abdom Imaging, 1996, 21(3):202-206.
[6] Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT[J]. Am J Roentgenol, 1997, 168(6):1439-1443.
[7] 殷允娟, 曾蒙苏, 李卉, 等. MRI对胰腺癌胰周血管侵犯的手术可切除性评价[J]. 临床放射学杂志, 2005, 24(9):792-796.
[8] 李卉, 曾蒙苏, 周康荣, 等. 胰腺癌侵犯胰周主要血管的CT表现分析[J]. 中华放射学杂志, 2005, 39(3):293-297.
[9] Katz MH, Fleming JB. Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant the-rapy is not reflected by radiographic indicators[J]. Cancer, 2012, 8(23):5749-5756.
[10] Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRlNOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg, 2015, 261(1):12-17.
[11] Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy[J]. Ann Surg Oncol, 2013, 20(7):2188-2196.
[12] Ferrone CR, Finkelstein DM, Thayer SP, et al. Periope-rative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma[J]. J Clin Oncol, 2006, 24(18):2897-2902.
[13] 徐华祥, 徐帅帅, 李硕, 等. 术前血清CA125预测血清CA19-9正常胰腺癌病人术后生存的价值[J]. 中国临床医学, 2020, 27(1):50-54.
[14] Abrams RA, Lowy AM, O′ Reilly EM, et al. Combined modality treatment of resectable and borderline resectable pancreas cancer; expert consensus statement[J]. Ann Surg Oncol, 2009, 16(7):1751-1756.
[15] 中国临床肿瘤学会胰腺癌专家委员会. 胰腺癌综合诊治中国专家共识(2014年版)[J]. 临床肿瘤学杂志, 2014,(4):358-370.
[16] 刘颖斌, 吴文广. 基于胰腺全系膜切除理念的胰头癌整块切除原则[J]. 外科理论与实践, 2015, 20(6):476-478.
[17] 刘颖斌, 吴文广. 胰头癌根治性切除的范围与争议[J]. 中华消化外科杂志, 2015, 14(8):615-618.
[18] 郝纯毅, 刘续宝, 孙备, 等. 可能切除胰腺癌治疗的现状与争议[J]. 中华消化外科杂志, 2018, 17(7):677-681.
[19] Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer:an intention to treat analysis[J]. Eur J Surg Oncol, 2018, 44(10):1619-1623.
[20] Lee JL, Kim SC, Kim JH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma[J]. Surgery, 2012, 152(5):851-862.
[21] 白雪莉, 粟伟, 李想, 等. 新辅助治疗对胰腺癌术后并发症的影响[J]. 中华外科杂志, 2018, 56(11):805-808.
[22] Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic bodyradiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma[J]. Acta Oncol, 2015, 54(7):979-985.
[23] Le Seodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially reseetable pancreatic adenocarcinoma:feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review[J]. Ann Oncol, 2009, 20(8):1387-1396.
[24] Leone F, Gatti M, Massucco P, et al. Induction gem-citabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for nemdjuvant treatment of locally advanced pancreatic cancer: a single institutional experience[J]. Cancer, 2012, 119(2):277-284.
[25] Lee SE, Jang JY, Kim MA, et al. Clinical implications of immunohistochemically demonstrated lymph node micrometastasis in resectable pancreatic cancer[J]. J Korean Med Sci, 2011, 26(7):881-885.
[26] Kim N, Han IW, Ryu Y, et al. Predictive nomogram for early recurrence after pancreatectomy in resectable pancreatic cancer: risk classification using preoperative clinicopathologic factors[J]. Cancers(Basel), 2020, 12(1):E137.
[27] Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma(PACT-15): a randomised, open-label, phase 2-3 trial[J]. Lancet Gastroenterol He-patol, 2018, 3(6):413-423.
[28] Motoi F, Kosuge T, Ueno H, et al. Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer(Prep-02 / JSAP05)[J]. Jpn J Clin Oncol, 2019, 49(2):190-194.
[29] Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative / neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages[J]. PLoS Med, 2010, 7(4):e1000267.
[30] Marchegiani G, Andrianello S, Nessi C, et al. Neoadjuvant therapy versus upfront resection for pancreatic cancer: the actual spectrum and clinical burden of postope-rative complications[J]. Ann Surg Oncol, 2018, 25(3):626-637.
[31] Dahdaleh FS, Naffouje SA, Hanna MH, et al. Impact of neoadjuvant systemic therapy on pancreatic fistula rates following pancreatectomy: a population-based propensity- matched analysis[J]. J Gastrointest Surg, 2021, 25(3):747-756.
Options
Outlines

/

〈 〉